The stock of The Medicines Company (NASDAQ:MDCO) is a huge mover today! About 1.52 million shares traded hands or 8.57% up from the average. The Medicines Company (NASDAQ:MDCO) has declined 1.14% since April 5, 2016 and is downtrending. It has underperformed by 3.10% the S&P500.
The move comes after 5 months positive chart setup for the $2.36 billion company. It was reported on Nov, 8 by Barchart.com. We have $55.38 PT which if reached, will make NASDAQ:MDCO worth $1.63B more.
The Medicines Company (NASDAQ:MDCO) Ratings Coverage
Out of 4 analysts covering The Medicines Co (NASDAQ:MDCO), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. The Medicines Co has been the topic of 12 analyst reports since August 28, 2015 according to StockzIntelligence Inc. The rating was maintained by RBC Capital Markets with “Outperform” on Tuesday, November 8. The rating was upgraded by Jefferies to “Hold” on Friday, August 28. As per Monday, March 21, the company rating was maintained by Chardan Capital Markets. The stock of The Medicines Company (NASDAQ:MDCO) earned “Outperform” rating by RBC Capital Markets on Monday, November 16. The stock of The Medicines Company (NASDAQ:MDCO) earned “Market Perform” rating by Oppenheimer on Monday, August 31. Leerink Swann maintained The Medicines Company (NASDAQ:MDCO) on Monday, August 31 with “Buy” rating. As per Wednesday, November 4, the company rating was initiated by Chardan Capital Markets. The stock of The Medicines Company (NASDAQ:MDCO) has “Buy” rating given on Saturday, August 29 by JP Morgan. RBC Capital Markets maintained it with “Outperform” rating and $46 target price in Monday, August 31 report.
According to Zacks Investment Research, “Medicines Company acquires, develops and commercializes biopharmaceutical products in late stages of development. U.S. Food and Drug Administration intends to approve its first product, Angiomax, for use in the treatment of patients with unstable angina undergoing coronary balloon angioplasty. The company is also developing Angiomax for additional potential applications for use in the treatment of ischemic heart disease, a condition which occurs when organs receive an inadequate supply of oxygen as a result of decreased blood flow.”
Insitutional Activity: The institutional sentiment increased to 1.27 in Q2 2016. Its up 0.14, from 1.13 in 2016Q1. The ratio improved, as 20 funds sold all The Medicines Company shares owned while 54 reduced positions. 25 funds bought stakes while 69 increased positions. They now own 81.19 million shares or 0.45% less from 81.56 million shares in 2016Q1.
Ashford Mgmt has 2.77% invested in the company for 368,392 shares. Blackrock Ltd last reported 93,136 shares in the company. Jane Street Limited Liability Corp has 0.01% invested in the company for 54,906 shares. Rock Springs Mgmt Limited Partnership accumulated 680,500 shares or 1.69% of the stock. Jpmorgan Chase holds 984,448 shares or 0.01% of its portfolio. Wexford Cap Ltd Partnership has 8,186 shares for 0.05% of their US portfolio. Blackrock Advsr Ltd Liability Co holds 32,401 shares or 0% of its portfolio. Northern Trust Corporation has 0.01% invested in the company for 847,646 shares. Blackrock Inv Mgmt Ltd last reported 0.01% of its portfolio in the stock. Barclays Public Limited Liability last reported 0% of its portfolio in the stock. Utd Ser Automobile Association has 0.01% invested in the company for 66,195 shares. Profund Advsr Limited holds 14,169 shares or 0.02% of its portfolio. Highvista Strategies Ltd Liability last reported 203,200 shares in the company. Teachers Retirement Systems Of The State Of Kentucky has 257,090 shares for 0.11% of their US portfolio. Moreover, Tiaa Cref Invest Limited Co has 0.01% invested in The Medicines Company (NASDAQ:MDCO) for 221,477 shares.
Insider Transactions: Since May 11, 2016, the stock had 2 buys, and 7 insider sales for $744,074 net activity. 8,623 The Medicines Company (NASDAQ:MDCO) shares with value of $344,920 were sold by MEANWELL CLIVE. Another trade for 15,000 shares valued at $527,295 was sold by CROUSE WILLIAM. Shares for $10.10M were bought by ESHELMAN FREDRIC N on Thursday, May 12. Cox Christopher T had bought 53,340 shares worth $2.00 million. Shares for $369,500 were sold by Savage Robert G. on Tuesday, May 24. On Wednesday, May 11 WYATT ELIZABETH H S sold $510,998 worth of the stock or 15,000 shares. $555,000 worth of The Medicines Company (NASDAQ:MDCO) was sold by Spigelman Melvin K.
More notable recent The Medicines Company (NASDAQ:MDCO) news were published by: Fiercebiotech.com which released: “The Medicines Company drops MDCO-216 as med comes up short” on November 08, 2016, also Zacks.com with their article: “The Medicines Company (MDCO) in Focus: Stock Rises 6%” published on October 19, 2016, Businesswire.com published: “The Medicines Company Announces Positive Top-Line Results from Day 90 Interim …” on October 18, 2016. More interesting news about The Medicines Company (NASDAQ:MDCO) were released by: Businesswire.com and their article: “The Medicines Company to Announce Third Quarter Financial Results on October …” published on October 17, 2016 as well as Businesswire.com‘s news article titled: “The Medicines Company Reports Third-Quarter 2016 Financial Results” with publication date: October 26, 2016.
MDCO Company Profile
The Medicines Company, incorporated on July 31, 1996, is a global biopharmaceutical company. The Company’s marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). The Company’s pipeline of acute and intensive care hospital products in development include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Firm sells a ready to use formulation of Argatroban and has a portfolio of over 10 generic drugs, which is referred as acute care generic products. The Firm sells over three of its acute care generic products, including midazolam, ondansetron and rocuronium.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.